Table 1 Baseline characteristics of patients treated with combination therapy or monotherapy
Overall (n = 148) | Patients with Combination therapy (n = 74) No. (%) | Patients with monotherapy (n = 74) No. (%) | P value | |
|---|---|---|---|---|
Age, median (range), years | 68 (33–88) | 68 (33–80) | 70.5 (46–88) | < 0.01 |
Sex, no. (%) | ||||
Male | 107 (72.3) | 54 (73.0) | 53 (71.6) | 0.85 |
Female | 41 (27.7) | 20 (27.0) | 21 (28.4) | |
Smoking status, no. (%) | ||||
Current or Former | 136 (91.9) | 69 (93.2) | 67 (90.5) | 0.55 |
Never | 12 (8.1) | 5 (6.8) | 7 (9.5) | |
Performance status, no. (%) | ||||
0 or 1 | 127 (85.8) | 69 (93.2) | 58 (78.4) | 0.01 |
≥ 2 | 21 (14.2) | 5 (6.8) | 16 (21.6) | |
Histological features, no. (%) | ||||
squamous cell carcinoma | 37 (25.0) | 16 (21.6) | 21 (28.4) | 0.34 |
non squamous cell carcinoma | 111 (75.0) | 58 (78.4) | 53 (71.6) | |
Recurrent after surgery, no. (%) | 54 (36.5) | 19 (25.7) | 35 (47.3) | 0.28 |
PD-L1 TPS, no. (%) | ||||
≥ 50% | 87 (58.8) | 21 (28.4) | 66 (89.2) | < 0.01 |
< 50% or unknown | 61 (41.2) | 53 (71.6) | 8 (10.8) | |